![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/20/2901762/0/en/Altamira-Therapeutics-Highlights-Newly-Published-Review-Article-Supporting-Use-of-Betahistine-in-Vertigo-Management.html
https://www.globenewswire.com/news-release/2024/05/28/2889166/0/en/Altamira-Therapeutics-Provides-Business-Update.html
https://www.globenewswire.com/news-release/2024/05/23/2887283/0/en/Altamira-Therapeutics-Announces-Dissemination-of-Positive-Results-from-Bentrio-Trial-in-Seasonal-Allergic-Rhinitis-Through-Social-Media-Channels-of-Top-Allergy-Journal.html
https://www.globenewswire.com/news-release/2024/05/01/2873265/0/en/Altamira-Therapeutics-Announces-Filing-of-Provisional-Patent-Application-for-OligoPhore-Nanoparticles-with-siRNA-Targeting-p65-Protein-in-Treatment-of-Cancer-and-Inflammation.html
https://www.globenewswire.com/news-release/2024/04/24/2868619/0/en/Altamira-Therapeutics-Announces-Publication-of-Positive-Results-from-Bentrio-Trial-in-Seasonal-Allergic-Rhinitis-in-Top-Peer-Reviewed-Journal.html
https://www.globenewswire.com/news-release/2024/04/10/2860704/0/en/Altamira-Therapeutics-Provides-Business-Update-Reports-Full-Year-2023-Financial-Results.html
https://www.globenewswire.com/news-release/2024/04/04/2857792/0/en/Altamira-Therapeutics-to-Host-Full-Year-2023-Financial-Results-and-Business-Update-Call-on-April-10-2024.html
https://www.globenewswire.com//news-release/2024/01/24/2815348/0/en/Altamira-Therapeutics-Files-Second-Provisional-Patent-Application-for-OligoPhore-Nanoparticles-Targeting-Different-KRAS-Mutations-in-Cancer-Treatment.html
https://www.globenewswire.com/news-release/2023/12/29/2802060/0/en/Altamira-Therapeutics-Regains-Compliance-with-Nasdaq-Minimum-Bid-Price-Requirement.html
https://www.globenewswire.com//news-release/2023/12/11/2793828/0/en/Altamira-Therapeutics-Provides-Investor-and-Business-Update.html